(Alkylamino)piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1IIIB with reduced replication phenotypes

Journal of Virology

Volumn 70, Issue 6, 1996, Pages 3698-3705

  Olmsted, Robert A ^a   Slade, David E ^a   Kopta, Laurice A ^a   Poppe, Susan M ^a   Poel, Toni J ^b   Newport, Sandra W ^a   Rank, Kenneth B ^c   Biles, Carolyn ^b   Morge, Raymond A ^b   Dueweke, Thomas J ^a   Yagi, Yoshihiko ^d   Romero, Donna L ^b   Thomas, Richard C ^b   Sharma, Satish K ^c   Gary Tarpley, W ^a  

^a Cancer and Infectious Diseases   (United States)

^b Medicinal Chemistry Research   (United States)

^c Chemical and Biological Screening   (United States)

^d Pharmacia and Upjohn   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(4,7 DICHLORO 2 BENZOXAZOLYLMETHYL)AMINO] 5 ETHYL 6 METHYL 2(1H) PYRIDONE; DELAVIRDINE; N [2 [4 [N (3 ISOPROPYLAMINO 2 PYRIDYL) N METHYLAMINO] 1 PIPERIDINYLCARBONYL] 5 INDOLYL]METHANESULFONAMIDE; N [2 [4 [N (3 TERT BUTYLAMINO 2 PYRIDYL) N ETHYLAMINO] 1 PIPERIDINYLCARBONYL] 5 INDOLYL]METHANESULFONAMIDE; N [2 [4 [N (3 TERT BUTYLAMINO 2 PYRIDYL) N METHYLAMINO] 1 PIPERIDINYLCARBONYL] 5 INDOLYL]METHANESULFONAMIDE; PIPERAZINE DERIVATIVE; R 88703; RNA DIRECTED DNA POLYMERASE INHIBITOR; U 104489; U 92884; U 95133; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG POTENCY; DRUG RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BLOTTING, WESTERN; DRUG RESISTANCE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 0029897567     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Balzarini, J., A. Karlsson, C. Meichsner, A. Paessens, G. Riess, E. DeClercq, and J.-P. Kleim. 1994. Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720. J. Virol. 68:7986-7992.
2. Balzarini, J., A. Karlsson, M.-J. Pérez-Pérez, M.-J. Camarasa, W. G. Tarpley, and E. DeClercq. 1993. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. J. Virol. 67:5353-5359.
3. Chattopadhyay, D., D. B. Evans, M. R. Deibel, Jr., A. F. Vosters, F. M. Eckenrode, H. M. Einspahr, J. O. Hui, A. G. Tomasselli, H. A. Zurcher-Neely, R. L. Hoinrikson, and S. K. Sharma. 1992. Purification and characterization of heterodimeric human immunodeficiency virus type 1 (HIV-1) reverse transcriptase produced by in vitro processing of p66 with recombinant HIV-1 protease. J. Biol. Chem. 267:14227-14232.
4. Chong, K. T., P. J. Pagano, and R. R. Hinshaw. 1994. Bisheteroarylpiperizine reverse transcriptase inhibitor combination with 3′-azido-3′-deoxythymidine or 2′,3′-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. Antimicrob. Agents Chemother. 38:288-293.
5. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis. and therapy. Science 267:483-489.
6. Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, D. Titus, T. Yang, H. Teppler, K. E. Squires, P. J. Deutsch, and E. A. Emini. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature (London) 374:569-571.
7. Dueweke, T. J., S. M. Poppe, D. L. Romero, S. M. Swaney, A. G. So, K. M. Downey, I. W. Althaus, F. Reusser, M. Busso, L. Resnick, D. L. Mayers, J. Lane, P. A. Aristoff, R. C. Thomas, and W. G. Tarpley. 1993. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 37:1127-1131.
8. Dueweke, T. J., T. Pushkarskaya, S. M. Poppe, S. M. Swaney, J. Q. Zhao. I. S. Y. Chen, M. Stevenson, and W. G. Tarpley. 1993. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA 90:4713-4717.
9. Eron, J. J., Y.-K. Chow, A. M. Caliendo, J. Videler, K. M. Devore, T. P. Cooley, H. A. Liebman, J. C. Kaplan, M. S. Hirsch, and R. T. D'Aquila. 1993. pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo. Antimicrob. Agents Chemother. 37:1480-1487.
10. Fan, N., D. B. Evans, K. B. Rank, R. C. Thomas, W. G. Tarpley, and S. K. Sharma. 1995. Mechanism of resistance to U-90152S and sensitization to L-697,661 by a proline to leucine change at residue 236 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. FEBS Lett. 359:233-238.
11. Fan, N., K. B. Rank, D. E. Slade, S. M. Poppe, L. A. Kopta, R. A. Olmsted, R. C. Thomas, W. G. Tarpley, and S. K. Sharma. A drug resistance mutation (G190E) in the inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase impairs processive DNA synthesis and RNA degradation. Submitted for publication.
12. Goldman, M. E., J. H. Nunberg, J. A. O'Brien, J. C. Quintero, W. A. Schleif, K. F. Freund, S. L. Gaul, W. S. Saari, J. S. Wai, J. M. Hoffman, P. S. Anderson, D. J. Hupe, E. A. Emini, and A. M. Stern. 1991 Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc. Natl. Acad. Sci. USA 88:6863-6867.
13. Gurgo, C., H.-G. Guo, G. Franchini, A. Aldovini, E. Collalti, K. Farrell, F. Wong-Staal, R. C. Gallo, and M. S. Reitz, Jr. 1988. Envelope sequences of two new United States HIV-1 isolates. Virology 164:531-536.
14. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (London) 373:123-126.
15. Kleim, J.-P., R. Bender, U.-M. Billhardt, C. Meichsner, G. Riess, M. Rösner, I. Winkler, and A. Paessens. 1993. Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication. Antimicrob. Agents Chemother. 37:1659-1664.
16. Kleim, J.-P., R. Bender, R. Kirsch, C. Meichsner, A. Paessens, and G. Rieb. 1994. Mutational analysis of residue 190 of human immunodeficiency virus type I reverse transcriptase. Virology 200:696-701.
17. Koyanagi, V., S. Miles, R. T. Mitsuyasu, J. E. Merrill, H. V. Vinters, and I. S. Y. Chen. 1987. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 236:819-822.
18. Mellors, J. W., G. E. Dutschman, G.-J. Im, E. Tramontano, S. R. Winkler, and Y.-C. Cheng. 1992. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mol. Pharmacol. 41:446-451.
19. Mellors, J. W., G.-J. Im, E. Tramontano, S. R. Winkler, D. J. Medina, G. E. Dutschman, H. Z. Bazmi, G. Piras, C. J. Gonzalez, and Y.-C. Cheng. 1993. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5,1-jk[1,4] benzodiazepin-2(1H)-thione (TIBO R82140). Mol. Pharmacol. 43:11-16.
20. Mellors, J. W., B. A. Larder, and R. F. Schinazi. 1995. Mutations in the HIV-1 reverse transcriptase and protease associated with drug resistance. Int. Antivir. News 3:8-13.
21. Merluzzi, V. J., K. D. Hargrave, M. Labadia, K. Grozinger, M. Skoog, J. C. Wu, C.-K. Shin, K. Eckner, S. Hattox, J. Adams, A. S. Rosenthal, R. Faanes, R. J. Eckner, R. A. Koup, and J. L. Sullivan. 1990. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250:1411-1413.
22. Nunberg, J. H., W. A. Schleif, E. J. Boots, J. A. O'Brien, J. C. Quintero, J. M. Hoffman, E. A. Emini, and M. E. Goldman. 1991. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J. Virol. 65:4887-4892.
23. Pagano, P. J., and K. T. Chong. Personal communication.
24. Pauwels, R., K. Andries, Z. Debyser, P. VanDaele, D. Schols, P. Stoffels, K. DeVreese, R. Woestenborghs, A.-M. Vandamme, C. G. M. Janssen, J. Anne, G. Cauwenbergh, J. Desmyter, J. Heykants, M. A. C. Janssen, E. DeClercq, and P. A. J. Janssen. 1993. Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhihition by a series of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:1711-1715.
25. Pauwels, R., K. Andries, J. Desmyter, D. Schols, M. J. Kukla, H. J. Breslin, A. Raeymaeckers, J. VanGelder, R. Woestenborghs, J. Heykants, K. Schellelens, M. A. C. Janssen, E. DeClerq, and P. A. J. Janssen. 1990. Potent and selective inhihition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature (London) 343:470-474.
26. Richman, D. D. 1993. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob. Agents Chemother. 37:1207-1213.
27. V. Richman, D. D., D. Havlir, J. Corbeil, D. Looney, C. Ignacio, S. A. Spector, J. Sullivan, S. Cheeseman, K. Barringer, D. Pauletti, C. K. Shih, M. Myers. and J. Griffin. 1994. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1660-1666.
28. Richman, D. D., C.-K, Shih, I. Lowry, J. Rose, P. Prodanovich, S. Golf, and J. Griffin. 1991. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. USA 88:11241-11245.
29. Romero, D. L., R. A. Morge, M. J. Genin, C. Biles, M. Busso, L. Resnick, I. W. Althaus, F. Reusser, R. C. Thomas, and W. G. Tarpley. 1993. Bis(hcteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of l-[(5-methanosulfonamido-lH-indol-2-yl)carboyl]-4-[3-[(1-methylethyl) amino]pyridinyl] piperazine monomethanesulfonate (U-90152S). a second generation clinical candidate. J. Med. Chem. 36:1505-1508.
30. Romero, D. L., R. C. Thomas, T. J. Poel, L. A. Kopta, R. A. Morge, C. Biles, J. Hosley, B. Kaiser, Y. Yagi, W. G. Tarpley, R. L. Voorman, R. A. Olmsted. and W. J. Adams. Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine containing BHAPs as broad spectrum HIV-1 reverse transcriptase inhibitors. Submitted for publication.
31. Saag, M. S., E. A. Emini, O. L. Laskin, J. Douglas, W. I. Lapidus, W. A. Schleif, R. J. Whitley, C. Hildebrand, V. W. Byrnes, J. C. Kappes, K. W. Anderson, F. E. Massari, G. M. Shaw, and the L-697,661 Working Group. 1993. A short term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. N. Engl. J. Med. 329:1065-1072.
32. Sardana, V. V., E. A. Emini, L. Gotlib, D. J. Graham, D. W. Lineberger, W. J. Long, A. J. Schlabach, J. A. Wolfgang, and J. H. Condra. 1992. Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors. J. Biol. Chem. 267:17526-17530.
33. Sharma, S. K., D. B. Evans, A. F. Vosters, T. J. McQuade, and W. G. Tarpley. 1991. Metal affinity chromatography of recombinant HIV-1 reverse transcriptase containing a human renin cleavable metal binding domain. Biotechnol. Appl. Biochem. 14:69-81.
34. Stevenson, M., S. Haggerty, C. Lamonica, A. M. Mann, C. Meier, and A. Wasiak. 1990. Cloning and characterization of human immunodeficiency virus type 1 variants diminished in the ability to induce syncytium-independent cytolysis. J. Virol. 64:3792-3803.
35. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag, and G. M. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature (London) 373:117-122.